Cardiology
Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
